�
Exclusive breastfeeding can increment a child's risk of developing rachitis because breast milk alone does not provide decent levels of vitamin D, a critical ingredient that helps to absorb calcium and build strong finger cymbals, the New York Times reports. Rickets develops when a child's vitamin D levels ar too low-toned and is characterized by the curved of a child's legs and the softening of other castanets. Some children are symptomless.
Darker-skinned children have a greater risk of vitamin D inadequacy than other children because they do not take in vitamin D as easily through the skin. Sunlight enables the skin to synthesize vitamin D.
Cases of nutritional rickets among infants and loretta Young children in the U.S. have been "accumulating over the concluding decade or so," and children with the term are more likely to be black or swarthy and have been breastfed exclusively for an extended period of time without vitamin supplementation, according to the Times. Some experts say that an increase in infants being solely breastfed, more children drink soda or juice and less milk, and children spending less time in the sunshine could contribute to rachitis re-emerging as a public health problem, the Times reports.
According to the Times, while physicians have known for days that undivided breastfeeding is associated with vitamin D deficiency in infants and rickets, many are "loath to tell anything that might deter breastfeeding." The American Academy of Pediatrics in 2003 recommended that infants world Health Organization are only breastfed receive vitamin D drops day-after-day.
According to one study on rickets and vitamin D that included mostly black and Hispanic infants and toddlers, 40% of the participants had abject levels of vitamin D, 12% were vitamin D deficient, 13 children showed evidence of bone loss and trey children had signs of rickets. The study, published in the June number Archives of Pediatrics & Adolescent Medicine, also establish that breastfeeding without vitamin supplementation was a significant risk factor for rickets.
Study generator Catherine Gordon, director of Children's Hospital Boston's bone health plan, said, "I completely support breastfeeding, and I think breast milk is the perfect nutrient, and the healthiest way to nourish an infant. However, we're finding so many mothers are vitamin D deficient themselves that the milk is thence deficient, so many babies can't sustain their levels up." She added, "They may lead off their lives vitamin D deficient, and then all they're acquiring is vitamin D deficient breast milk" (Rabin, New York Times, 8/26).
Reprinted with kind permission from http://www.kaisernetwork.org. You canful view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for e-mail delivery at http://www.kaisernetwork.
Monday 1 September 2008
Friday 22 August 2008
Multaq(R) (dronedarone) Granted FDA Priority Review For Patients With Atrial Fibrillation
�Sanofi-aventis
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority limited review status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The priority review time period
begins on July 31, 2008.
The priority review is given to applications in which a new
indication or new drug product, if approved, has the voltage to deliver a
safe and effective therapy where no satisfactory alternative exists
compared to currently useable therapies or marketed products.
A registration dossier is also under regulatory limited review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are pleased that the FDA has designated Multaq(R) for precedency
review," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly decreased the risk of
cardiovascular hospitalizations or death from any causal agent in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects about 2.5 million people in the United States, as well as 4.5
million people in the European Union and is rising as a growing public
health concern due to an ripening population. Patients suffering from atrial
fibrillation have double the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart failure.
Furthermore atrial fibrillation considerably impairs patients' lives,
mainly because of their inability to execute normal daily activities due to
complaints of palpitations, chest botheration, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand bring up Multaq(R)) is an investigational new discussion
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and discourse of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not hold the i radical
and did not show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a ahead global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as outlined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include intersection development, product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
sane, investors ar cautioned that forward-looking information and
statements are issue to various risks and uncertainties, many of which
are hard to call and loosely beyond the control of
sanofi-aventis, that could causal agency actual results and developments to take issue
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among former things, the uncertainties underlying in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory government, such as the FDA or the EMEA, regarding
whether and when to approve whatsoever drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of guarantee
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutical alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' yearly report on Form 20-F for the year over December 31,
2007. Other than as required by applicable law of nature, sanofi-aventis does not
undertake any obligation to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority limited review status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The priority review time period
begins on July 31, 2008.
The priority review is given to applications in which a new
indication or new drug product, if approved, has the voltage to deliver a
safe and effective therapy where no satisfactory alternative exists
compared to currently useable therapies or marketed products.
A registration dossier is also under regulatory limited review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are pleased that the FDA has designated Multaq(R) for precedency
review," said Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly decreased the risk of
cardiovascular hospitalizations or death from any causal agent in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects about 2.5 million people in the United States, as well as 4.5
million people in the European Union and is rising as a growing public
health concern due to an ripening population. Patients suffering from atrial
fibrillation have double the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart failure.
Furthermore atrial fibrillation considerably impairs patients' lives,
mainly because of their inability to execute normal daily activities due to
complaints of palpitations, chest botheration, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand bring up Multaq(R)) is an investigational new discussion
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and discourse of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not hold the i radical
and did not show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a ahead global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as outlined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts.
These statements include intersection development, product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
sane, investors ar cautioned that forward-looking information and
statements are issue to various risks and uncertainties, many of which
are hard to call and loosely beyond the control of
sanofi-aventis, that could causal agency actual results and developments to take issue
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among former things, the uncertainties underlying in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory government, such as the FDA or the EMEA, regarding
whether and when to approve whatsoever drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of guarantee
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutical alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' yearly report on Form 20-F for the year over December 31,
2007. Other than as required by applicable law of nature, sanofi-aventis does not
undertake any obligation to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
Tuesday 12 August 2008
New Research Questions Use Of Common Fertility Treatments
�
A raw study promulgated on bmj.com
has found that fertility is not improved in sterile couples wHO have
been treated with long-established medical interventions. The team of
researchers lED by the University of Aberdeen has called for UK and
national guidelines to be reviewed with this new evidence that
challenges current practices.
In the UK, one in seven couples experience infertility. Of these, about
25% of the infertility is unexplained, and the criterion treatment
includes a body of common interventions that have been used for years
and have been issued by the National Institute for Health and Clinical
Excellence (NICE).
The research squad set out to compare two specific interventions with
expectant management (i.e., no intervention). From quatern teaching hospitals
and a district general hospital in Scotland, they recruited a sample of
580 women who own had unexplained infertility for over deuce years. The
women were arbitrarily assigned such that one group had no medical
intervention and tried naturally to become pregnant, a second radical
took oral clomifene citrate (CC) to correct subtle ovulatory
disfunction, and a third group received unstimulated intra-uterine
insemination (IUI) of sperm.
During the course of the study, 101 women became pregnant and had a
alive birth. The birth pace for women with no intervention was 17%, and
the rates for the oral CC group and the IUI group were 14% and 23%,
respectively. According to the researchers, the 6% difference between
the IUI and the non-intervention group is no large enough for the
results to suggest a meaningful and significant advance in the live
parentage rate.
Many women suffered from side effects that included: pain, bloating,
hot flushes, nausea and headaches. These affected approximately 10 to 20% of
women, most of whom were taking oral CC. Also, it is worth noting that
satisfaction was higher in the groups of women being actively treated -
as they were reassured by the treatment process - compared to women who
received no intervention.
"These interventions, which have been in use for many years, ar
unlikely to be more effective than no treatment. These results
challenge stream practice, as endorsed by a national guideline in the
UK," conclude the authors.
Tarek El-Toukhy and Yacoub Khalaf (Assisted Conception Unit at Guy's
and St Thomas' NHS Foundation Trust) write in an incidental editorial
that: "As a direct resolution of the lack of evidence, many couples with
unexplained infertility endure (and even request) expensive,
potentially hazardous, and often unnecessary treatments." There is a
need for high quality clinical trials as well as better information for
patients to determine the best treatments in light of strength and
adverse effects. El-Toukhy and Khalaf also call for the current NICE
guidelines to be reviewed with this inquiry in mind.
Clomifene citrate or unstimulated intrauterine insemination
compared with anticipative management for unexplained sterility:
pragmatic randomized controlled trial
S Bhattacharya, K Harrild, J Mollison, S Wordsworth, C Tay, A Harrold,
D McQueen, H Lyall, L Johnston, J Burrage, S
Grossett, H Walton, J Lynch, A
Johnstone, S Kini, A Raja, A Templeton
BMJ (2008). 337: a716.
doi:10.1136/bmj.a716
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
A raw study promulgated on bmj.com
has found that fertility is not improved in sterile couples wHO have
been treated with long-established medical interventions. The team of
researchers lED by the University of Aberdeen has called for UK and
national guidelines to be reviewed with this new evidence that
challenges current practices.
In the UK, one in seven couples experience infertility. Of these, about
25% of the infertility is unexplained, and the criterion treatment
includes a body of common interventions that have been used for years
and have been issued by the National Institute for Health and Clinical
Excellence (NICE).
The research squad set out to compare two specific interventions with
expectant management (i.e., no intervention). From quatern teaching hospitals
and a district general hospital in Scotland, they recruited a sample of
580 women who own had unexplained infertility for over deuce years. The
women were arbitrarily assigned such that one group had no medical
intervention and tried naturally to become pregnant, a second radical
took oral clomifene citrate (CC) to correct subtle ovulatory
disfunction, and a third group received unstimulated intra-uterine
insemination (IUI) of sperm.
During the course of the study, 101 women became pregnant and had a
alive birth. The birth pace for women with no intervention was 17%, and
the rates for the oral CC group and the IUI group were 14% and 23%,
respectively. According to the researchers, the 6% difference between
the IUI and the non-intervention group is no large enough for the
results to suggest a meaningful and significant advance in the live
parentage rate.
Many women suffered from side effects that included: pain, bloating,
hot flushes, nausea and headaches. These affected approximately 10 to 20% of
women, most of whom were taking oral CC. Also, it is worth noting that
satisfaction was higher in the groups of women being actively treated -
as they were reassured by the treatment process - compared to women who
received no intervention.
"These interventions, which have been in use for many years, ar
unlikely to be more effective than no treatment. These results
challenge stream practice, as endorsed by a national guideline in the
UK," conclude the authors.
Tarek El-Toukhy and Yacoub Khalaf (Assisted Conception Unit at Guy's
and St Thomas' NHS Foundation Trust) write in an incidental editorial
that: "As a direct resolution of the lack of evidence, many couples with
unexplained infertility endure (and even request) expensive,
potentially hazardous, and often unnecessary treatments." There is a
need for high quality clinical trials as well as better information for
patients to determine the best treatments in light of strength and
adverse effects. El-Toukhy and Khalaf also call for the current NICE
guidelines to be reviewed with this inquiry in mind.
Clomifene citrate or unstimulated intrauterine insemination
compared with anticipative management for unexplained sterility:
pragmatic randomized controlled trial
S Bhattacharya, K Harrild, J Mollison, S Wordsworth, C Tay, A Harrold,
D McQueen, H Lyall, L Johnston, J Burrage, S
Grossett, H Walton, J Lynch, A
Johnstone, S Kini, A Raja, A Templeton
BMJ (2008). 337: a716.
doi:10.1136/bmj.a716
Click
Here to View Journal Web Site
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
Wednesday 6 August 2008
'Mummy' dearest at international boxoffice
Sequel takes in $61.2 mile from 27 countries
With 1 month to go before the trek back to school begins, the blockbuster action adventures keep gushing out in assembly-line mode, with the past weekend's new
With 1 month to go before the trek back to school begins, the blockbuster action adventures keep gushing out in assembly-line mode, with the past weekend's new
Dani Ro
Artist: Dani Ro
Genre(s):
R&B: Soul
Electronic
Discography:
Enplastico 2003
Year: 2007
Tracks: 11
El Repartidor De Hi
Year:
Tracks: 15
Thergothon
Artist: Thergothon
Genre(s):
Metal
Discography:
Fhtagn-Nagh Yog-Sothoth
Year: 2005
Tracks: 4
Stream From The Heavens
Year: 1994
Tracks: 6
Fhtagn-Nag Yog-Sothoth
Year: 1991
Tracks: 4
Wednesday 2 July 2008
Cover Story: Jen's Baby Plan
In September 2005, just months after her split from then-husband Brad Pitt, Jennifer Aniston confessed to Vanity Fair her desire to have a child.
"There's an amazing man who's wandering the streets right now, who's the father of my children," she said. "In five years, I would hope to be married and have a kid...Maybe it's a fairytale, but I believe in happily ever after."
Three years since making that statement, Jen seems to have finally found her prince charming in a tall, dark and handsome younger man, nine years her junior to be exact, John Mayer.
"I've never seen Jen this happy � or this in love," a pal of the actress tells OK!. "Not since Brad."
Just three months into their relationship, the couple has jet-setted across the world, shacked up for cozy evenings together in her Beverly Hills home and even met each other's inner circles (John has gotten the thumbs up from Jen's BFF Courteney Cox and her husband David Arquette).
And, as of last week, the actress flew to Europe to accompany John, 30, on his European tour, where on June 28 witnesses spotted the two getting hot and heavy at La Famiglia restaurant in London. That same day, Jen was the proud girlfriend, taking photos of her man from the side of the stage while he performed in concert at the Hard Rock Calling Festival.
It's no wonder Jen wants to move fast. While she has a body and energy level most girls in their 20's would die for, not even she can fight time. Jen, who turns 40 on her next birthday, knows that now is her chance to have that long-wished for baby, and she wants to have it with John!
"It wouldn't be much of a surprise at all if they moved in together by the year's end," a friend of Jen's tells OK!. "And if they do, you can bet that there will be serious discussions about having children."
For the entire story on Jen's pregnancy plan, pick up the new OK! � on sale everywhere Wednesday!
See Also
Subscribe to:
Posts (Atom)